Toxicological and metabolic considerations for histone deacetylase inhibitors

Bibliography

• Allfrey VG, Mirsky AE. Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis. Science 1964;144(3618):559
   PubMed Web of Science ®Google Scholar
• Riggs MG, Whittaker RG, Neumann JR, n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977;268(5619):462-4
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265(28):17174-9
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 1987;47(14):3688-91
   PubMed Web of Science ®Google Scholar
• Boffa LC, Vidali G, Mann RS, Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 1978;253(10):3364-6
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37(4):391-400
   PubMed Web of Science ®Google Scholar
• Shukla V, Vaissiere T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008;637(1-2):1-15
   PubMed Web of Science ®Google Scholar
• Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010;1799(10-12):717-25
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2011;31(5):537-51
   PubMed Web of Science ®Google Scholar
• Richon VM, Webb Y, Merger R, Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93(12):5705-8
   PubMed Web of Science ®Google Scholar
• Beck J, Fischer T, Rowinsky Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589: a novel histone deacetylase inhibitor. American Society of Clincal Oncology; 2004. p. 201
   Google Scholar
• Plumb JA, Williams RJ, Finn PW, Inhibition of tumour cell growth in vitro and in vivo by the histone deacetylase inhibitor PXD101. American Association for Cancer Research; 2002. p. 333-4
   Google Scholar
• Plumb JA, Finn PW, Williams RJ, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2(8):721-8
   PubMed Web of Science ®Google Scholar
• Armeanu S, Pathil A, Venturelli S, Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2005;42(2):210-17
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241(1):126-33
   PubMed Web of Science ®Google Scholar
• Saito A, Yamashita T, Mariko Y, A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96(8):4592-7
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou N, Fournel M, Antitumor activities of MGCD0103, a novel and isotype-selective histone deacetylase inhibitor. 16th EORTC-NCI-ACCR (Symposium on Molecular Targets and Cancer Therapeutics); 2004
   Google Scholar
• Fournel M, Bonfils C, Hou Y, MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7(4):759-68
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Hopf C, Savitski MM, Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29(3):255-65
   PubMed Web of Science ®Google Scholar
• Mohamed EA, Zhao Y, Meshali MM, Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci 2012;101(10):3787-98
   PubMed Web of Science ®Google Scholar
• Kantharaj E, Jayaraman R. Histone deacetylase inhibitors as therapeutic agents for cancer therapy: drug metabolism and pharmacokinetic properties. In: Rundfeldt C, editor. Drug development - a case study based insight into modern strategies. InTech; 2011. p. 654
   Google Scholar
• Kelly WK, Richon VM, O'Connor O, Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-88
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
   PubMed Web of Science ®Google Scholar
• Sandhu P, Andrews PA, Baker MP, Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. Drug Metab Lett 2007;1(2):153-61
   PubMedGoogle Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
   PubMed Web of Science ®Google Scholar
• Rubin EH, Agrawal NG, Friedman EJ, A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12(23):7039-45
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Yamamoto N, Yamada Y, Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 2009;100(9):1728-34
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kato H, Kobayashi Y, Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010;101(1):196-200
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Kummar S, Sarantopoulos J, Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010;28(29):4507-12
   PubMed Web of Science ®Google Scholar
• http://www.accessdata.fda.gov
   Google Scholar
• Balliet RM, Chen G, Gallagher CJ, Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009;69(7):2981-9
   PubMed Web of Science ®Google Scholar
• Wong NS, Seah EZh, Wang LZ, Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics 2011;21(11):760-8
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney ML, Schwartz L, Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24(1):166-73
   PubMed Web of Science ®Google Scholar
• Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011;20(2):287-95
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
   PubMed Web of Science ®Google Scholar
• Doi T, Hamaguchi T, Shirao K, Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Van Cutsem E, Dumez H, Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26(5):483-8
   PubMed Web of Science ®Google Scholar
• Crump M, Coiffier B, Jacobsen ED, Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19(5):964-9
   PubMed Web of Science ®Google Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94(10):1375-82
   PubMed Web of Science ®Google Scholar
• Bradley D, Rathkopf D, Dunn R, Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009;115(23):5541-9
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29(9):1198-203
   PubMed Web of Science ®Google Scholar
• Luu TH, Morgan RJ, Leong L, A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008;14(21):7138-42
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26(1):81-7
   PubMed Web of Science ®Google Scholar
• Munster PN, Rubin EH, Van Belle S, A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009;15(22):7077-84
   PubMed Web of Science ®Google Scholar
• Giavini E. Comment on developmental toxicity evaluation on vorinostat and relationship with HDAC inhibition. Birth Defects Res B Dev Reprod Toxicol 2007;80(5):417-18; author reply 19-20
   PubMed Web of Science ®Google Scholar
• Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 2007;80(1):57-68
   PubMed Web of Science ®Google Scholar
• Kavanaugh SM, Kavanaugh SA, White LA, Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010;67(10):793-7
   PubMed Web of Science ®Google Scholar
• Konsoula Z, Cao H, Velena A, Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors. Mol Cancer Ther 2009;8(10):2844-51
   PubMed Web of Science ®Google Scholar
• Clive S, Woo M, Stewart M, Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using 14C- panobinostat. ASCO Annual Meeting; 2009
   Google Scholar
• Giles F, Fischer T, Cortes J, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12(15):4628-35
   PubMed Web of Science ®Google Scholar
• Morita S, Oizumi S, Minami H, Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 2011;30(5):1950-7
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Spencer A, Prince HM, Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with advanced Hematologic Malignancies (abstract). ASH Annual Meeting Abstracts; 2008
   Google Scholar
• Prince HM, George D, Patnaik A, Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma. ASCO Annual Meeting Proceedings; 2007
   Google Scholar
• Fukutomi A, Hatake K, Matsui K, A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 2012;30(3):1096-106
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Frank R, Dandamudi UB, The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 2012;69(2):555-62
   PubMed Web of Science ®Google Scholar
• Hamberg P, Woo MM, Chen LC, Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011;68(3):805-13
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14(14):4500-10
   PubMed Web of Science ®Google Scholar
• Dimicoli S, Jabbour E, Borthakur G, Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 2012;87(1):127-9
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 2011;67(6):1273-9
   PubMed Web of Science ®Google Scholar
• Wang L, Goth BC, Lwin TW, Phase I pharmacokinetic and metabolic pathway of belinostat in patients with hepatocellular carcinoma (abstract). ASCO Annual Meeting; 2010
   Google Scholar
• Gimsing P, Hansen M, Knudsen LM, A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008;81(3):170-6
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4(1):97-101
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Hirte H, Colgan T, Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 2010;46(9):1573-9
   PubMed Web of Science ®Google Scholar
• Giaccone G, Rajan A, Berman A, Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011;29(15):2052-9
   PubMed Web of Science ®Google Scholar
• Cashen A, Juckett M, Jumonville A, Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012;91(1):33-8
   PubMed Web of Science ®Google Scholar
• Golay J, Cuppini L, Leoni F, The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007;21(9):1892-900
   PubMed Web of Science ®Google Scholar
• Carta S, Tassi S, Semino C, Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 2006;108(5):1618-26
   PubMed Web of Science ®Google Scholar
• Furlan A, Monzani V, Reznikov LL, Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011;17(5-6):353-62
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150(4):446-55
   PubMed Web of Science ®Google Scholar
• Galli M, Salmoiraghi S, Golay J, A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010;89(2):185-90
   PubMed Web of Science ®Google Scholar
• Shigematsu N, Ueda H, Takase S, FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo) 1994;47(3):311-14
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
   PubMed Web of Science ®Google Scholar
• Li Z, Chan KK. A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. J Pharm Biomed Anal 2000;22(1):33-44
   PubMed Web of Science ®Google Scholar
• Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012;18(13):3509-15
   PubMed Web of Science ®Google Scholar
• Woo S, Gardner ER, Chen X, Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009;15(4):1496-503
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256-67
   PubMed Web of Science ®Google Scholar
• Shiraga T, Tozuka Z, Ishimura R, Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005;28(1):124-9
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Byrd J, Marcucci G, Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom 2003;17(8):757-66
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T, Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24(22):3678-85
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Lamborn KR, Kuhn JG, A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: north American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011;13(5):509-16
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006;5(1):57-60
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28(29):4485-91
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117(2):336-42
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-34
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Rankin C, Hoff PM, Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2009;27(5):469-75
   PubMed Web of Science ®Google Scholar
• Haigentz M, Kim M, Sarta C, Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012;48(12):1281-8
   PubMed Web of Science ®Google Scholar
• Klimek VM, Fircanis S, Maslak P, Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14(3):826-32
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12(12):3762-73
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Huang Y, Dai Z, Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005;314(1):467-75
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Foraker AB, Swaan PW, Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther 2005;313(1):268-76
   PubMed Web of Science ®Google Scholar
• Yamada H, Arakawa Y, Saito S, Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leuk Res 2006;30(6):723-34
   PubMed Web of Science ®Google Scholar
• Robey RW, Zhan Z, Piekarz RL, Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006;12(5):1547-55
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O'Bryant CL, A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517-25
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Gardner ER, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411-17
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90
   PubMed Web of Science ®Google Scholar
• Acharya MR, Karp JE, Sausville EA, Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006;24(5):367-75
   PubMed Web of Science ®Google Scholar
• Acharya MR, Sparreboom A, Sausville EA, Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006;57(3):275-81
   PubMed Web of Science ®Google Scholar
• Simonini MV, Camargo LM, Dong E, The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103(5):1587-92
   PubMed Web of Science ®Google Scholar
• Hooker JM, Kim SW, Alexoff D, Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using positron emission tomography. ACS Chem Neurosci 2010;1(1):65-73
   PubMed Web of Science ®Google Scholar
• Zhou N, Moradei O, Raeppel S, Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008;51(14):4072-5
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(4):981-9
   PubMed Web of Science ®Google Scholar
• Siu LL, Pili R, Duran I, Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26(12):1940-7
   PubMed Web of Science ®Google Scholar
• Bonfils C, Kalita A, Dubay M, Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008;14(11):3441-9
   PubMed Web of Science ®Google Scholar
• Blum KA, Advani A, Fernandez L, Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009;147(4):507-14
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12(13):1222-8
   PubMed Web of Science ®Google Scholar
• Cai YY, Yap CW, Wang Z, Solubilization of vorinostat by cyclodextrins. J Clin Pharm Ther 2010;35(5):521-6
   PubMed Web of Science ®Google Scholar
• Bishton MJ, Harrison SJ, Martin BP, Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011;117(13):3658-68
   PubMed Web of Science ®Google Scholar
• Shultz MD, Cao X, Chen CH, Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem 2011;54(13):4752-72
   PubMed Web of Science ®Google Scholar
• Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15(12):3970-7
   PubMed Web of Science ®Google Scholar
• Steele N, Finn P, Brown R, Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009;100(5):758-63
   PubMed Web of Science ®Google Scholar
• Robey RW, Chakraborty AR, Basseville A, Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011;8(6):2021-31
   PubMedGoogle Scholar
• Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13(24):7237-42
   PubMed Web of Science ®Google Scholar